We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · October 27, 2021

Tirzepatide in Type 2 Diabetes With Increased Cardiovascular Risk

The Lancet

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
Lancet 2021 Oct 18;[EPub Ahead of Print], S Del Prato, SE Kahn, I Pavo, GJ Weerakkody, Z Yang, J Doupis, D Aizenberg, AG Wynne, JS Riesmeyer, RJ Heine, RJ Wiese

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading